Furthermore, 8.7% of CCA patients retained the FIG-ROS fusion gene that activates downstream signaling molecules, including STAT3 and AKT [1], thus accelerating tumorigenesis in a mouse model of iCCA holding KRAS and TP53 mutations [6]. The gene discussed is KRAS; the disease is cholangiocarcinoma.